Rockland Immunochemicals and LIMR Development Form Antibody Commercialization Partnership

GILBERTSVILLE, Pa.--(BUSINESS WIRE)--Rockland Immunochemicals Inc., a biotechnology company focusing on antibodies and antibody-based tools for basic research, diagnostic assay development and preclinical studies is pleased to announce a new licensing venture with LIMR Development, Inc. (LDI), the business development subsidiary of the Lankenau Institute for Medical Research (LIMR)
MORE ON THIS TOPIC